Skip to main content
Onesource Specialty Pharma Limited logo

Onesource Specialty Pharma Limited — Investor Relations & Filings

Ticker · ONESOURCE ISIN · INE013P01021 LEI · 335800TP5C932B9IQT98 BSE.NS Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-06-11 Regulatory Filings
Country IN India
Listing BSE.NS ONESOURCE

About Onesource Specialty Pharma Limited

https://www.onesourcecdmo.com/

Onesource Specialty Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) providing integrated solutions for complex pharmaceutical products. The company focuses on the development and large-scale manufacturing of specialty injectables, softgel capsules, and complex formulations. Its service portfolio encompasses the entire product lifecycle, including formulation development, clinical trial supply, and commercial-stage production. Onesource operates advanced manufacturing facilities designed to meet global regulatory standards, catering to diverse therapeutic areas. By leveraging technical expertise in sterile products and differentiated dosage forms, the organization supports global pharmaceutical partners in bringing high-entry-barrier medicines to market. The platform is built on a foundation of quality compliance and operational excellence to ensure the delivery of critical healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's participation in an investor group meeting. It references Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure obligations for listed companies. The content is an announcement of an event (investor meeting) and does not contain financial data, report details, or any form of financial results or management discussion. It is not a report itself but a regulatory announcement about an upcoming investor engagement. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new biosimilars manufacturing partnership between OneSource Specialty Pharma Limited and Xbrane Biopharma AB. It includes details about the partnership, company descriptions, and contact information. There are no financial statements, regulatory filings, or detailed financial data presented. The document is an announcement of a business partnership and related corporate news, not a financial report, regulatory filing, or management discussion. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a corporate announcement that does not fit other specific categories.
2025-06-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated June 10, 2025, announcing that OneSource Specialty Pharma Limited's flagship facility in Bangalore has maintained its USFDA compliance status with a Voluntary Action Indicated (VAI) classification after an inspection. The content focuses on regulatory compliance and inspection results rather than financial performance, management changes, or shareholder information. It is a regulatory announcement about inspection outcomes and compliance status, not a full audit report or annual report. The document length is 4093 characters, which is relatively short and typical for a press release. There is no detailed financial data or management discussion. Therefore, the document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-06-10 English
Updates
Regulatory Filings
2025-06-10 English
Credit Rating
Regulatory Filings
2025-06-04 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding non-compliance with SEBI Listing Regulations, specifically Regulation 19(1)/(2) about the composition of the Nomination and Remuneration Committee. It details the receipt of a notice, the fine imposed, corrective actions taken by the company, and the impact on financials. The document is a regulatory compliance announcement related to governance and regulatory adherence, not a full report or financial statement. It does not contain financial data or detailed management discussion but is a regulatory filing informing the exchanges and public about the non-compliance and remedial steps. The document length is under 5,000 characters and is a disclosure letter, fitting the Regulatory Filings (RNS) category rather than a full governance report or management announcement.
2025-05-30 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.